Evaluation of SARS-CoV-2-Specific IgY Antibodies: Production, Reactivity, and Neutralizing Capability against Virus Variants
International Journal of Molecular Sciences · 21.07.2024 · 25 (14) · 7976
DOI: 10.3390/ijms25147976 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 21.07.2024. Verfasst von Jacob Schön und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, 17493 Greifswald, Germany. Hauptthemen laut MEDLINE: SARS-CoV-2, Immunoglobulins, Chickens, Antibodies, Neutralizing. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Virus Archive GLOBAL (EVA-GLOBAL) project, European Union’s Horizon 2020 research and innovation program.
Abstract (Originalsprache)
The emergence of SARS-CoV-2 in late 2019 initiated a global pandemic, which led to a need for effective therapeutics and diagnostic tools, including virus-specific antibodies. Here, we investigate different antigen preparations to produce SARS-CoV-2-specific and virus-neutralizing antibodies in chickens (n = 3/antigen) and rabbits (n = 2/antigen), exploring, in particular, egg yolk for large-scale production of immunoglobulin Y (IgY). Reactivity profiles of IgY preparations from chicken sera and yolk and rabbit sera were tested in parallel. We compared three types of antigens based on ancestral SARS-CoV-2: an inactivated whole-virus preparation, an S1 spike-protein subunit (S1 antigen) and a receptor-binding domain (RBD antigen, amino acids 319–519) coated on lumazine synthase (LS) particles using SpyCather/SpyTag technology. The RBD antigen proved to be the most efficient immunogen, and the resulting chicken IgY antibodies derived from serum or yolk, displayed strong reactivity with ELISA and indirect immunofluorescence and broad neutralizing activity against SARS-CoV-2 variants, including Omicron BA.1 and BA.5. Preliminary in vivo studies using RBD–lumazine synthase yolk preparations in a hamster model showed that local application was well tolerated and not harmful. However, despite the in vitro neutralizing capacity, this antibody preparation did not show protective effect. Further studies on galenic properties seem to be necessary. The RBD–lumazine antigen proved to be suitable for producing SARS-CoV-2 specific antibodies that can be applied to such therapeutic approaches and as reference reagents for SARS-CoV-2 diagnostics, including virus neutralization assays.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, 17493 Greifswald, Germany.
- Department of Experimental Animal Facilities and Biorisk Management, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, 17493 Greifswald, Germany.
ORCID-Profile: Nico Joël Halwe, Donata Hoffmann, Sven Reiche, Christian Grund
Förderung
- European Virus Archive GLOBAL (EVA-GLOBAL) project
- European Union’s Horizon 2020 research and innovation program
Zitieren
APA
Schön, J., Aebischer, A., Halwe, N. J., Ulrich, L., Hoffmann, D., Reiche, S., Beer, M., & Grund, C. (2024). Evaluation of SARS-CoV-2-Specific IgY Antibodies: Production, Reactivity, and Neutralizing Capability against Virus Variants. International Journal of Molecular Sciences, 25(14), 7976. https://doi.org/10.3390/ijms25147976
Vancouver
Schön J, Aebischer A, Halwe NJ, Ulrich L, Hoffmann D, Reiche S, et al. Evaluation of SARS-CoV-2-Specific IgY Antibodies: Production, Reactivity, and Neutralizing Capability against Virus Variants. International Journal of Molecular Sciences. 2024;25(14):7976. doi:10.3390/ijms25147976
BibTeX
@article{Schn2024,
author = {Schön, Jacob and Aebischer, Andrea and Halwe, Nico Joël and Ulrich, Lorenz and Hoffmann, Donata and Reiche, Sven and Beer, Martin and Grund, Christian},
title = {Evaluation of SARS-CoV-2-Specific IgY Antibodies: Production, Reactivity, and Neutralizing Capability against Virus Variants},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {14},
pages = {7976},
doi = {10.3390/ijms25147976}
}
EUVIMED